Skip to content
value.today
Synlogic, Inc. logo

Synlogic, Inc.

SYBX
$44 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2025
Net income
$-1 M
SEC filing
Employees
—

Synlogic, Inc. in brief

Synlogic, Inc. is a listed company in the Biotechnology industry, based in Winchester, Massachusetts, USA. Its last known market value was $44 M (January 2024); there is no current figure. Its shares trade under the symbol SYBX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Synlogic, Inc.

We are a biopharmaceutical company that previously advanced novel therapeutics to transform the care of serious diseases. We focused on rare metabolic disorders, with our lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). Both PKU and HCU are caused by inborn errors of metabolism, and present significant need for innovation due to limitations of both efficacy and safety in the currently available medical treatment options. In February 2024, we made the decision to discontinue Synpheny-3, our pivotal study of our lead product candidate, labafenogene marselecobac (SYNB1934), as a potential treatment for PKU. The decision to end Synpheny-3 is based on results of an internal review in advance of an upcoming independent Data Monitoring Committee (DMC) assessment, which indicated the trial was unlikely to meet its primary endpoint. The decision was not based on concerns regarding safety or tolerability. As a result, our current corporate strategy is focused on pursuing strategic initiatives to enhance stockholder value, including but not limited to, a merger or the sale of the Company. Our strategic process is both active and ongoing and includes a range of interactions with transaction counterparties. Thus, we believe it is in our stockholders’ best interest to allow sufficient opportunity to pursue and consummate one or more such transactions and to consider additional alternatives that may materialize in the future. However, there can be no assurance that such activities will result in any agreements or transactions that will enhance shareholder value. Further, any strategic transaction that is completed ultimately may not deliver the anticipated benefits or enhance shareholder value.

From the company's annual report filed with the US SEC: read the report

Synlogic, Inc. timeline

4 events, 2011–2023
  1. 2011
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2015
  4. 🔔
    Initial public offering as Mirna Therapeutics, Inc.
    Final prospectus filed with the SEC on 1 October 2015; shares registered for exchange trading on 23 September 2015.
  5. 2017
  6. ✎
    Renamed Synlogic, Inc.
    Formerly Mirna Therapeutics, Inc..
  7. 2023
  8. 💰
    Record revenue of $3 million
    FY2023, the highest of the 6 years on record.

Events of Synlogic, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$41 M$82 M$123 M$164 M20202021202220232024

World rank over time

▼ down 5,837 places since 2020
2020-01-01: #19745#19,74520202021-01-01: #19252#19,25220212022-01-07: #20713#20,71320222022-12-25: #25281#25,28120222023-07-30: #27235#27,23520232024-01-05: #25582#25,5822024

Rank in USA: #3,837 (Jan 2020) · #3,853 (Jan 2021) · #4,081 (Jan 2022) · #4,794 (Dec 2022) · #4,970 (Jul 2023) · #4,128 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-8.4%
Liabilities / assets
23.2%
Revenue growth
-99.7%
R&D / revenue
91500.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $3M, net income $-48M$3MFY18Fiscal year ending Dec 2019: revenue $2M, net income $-51M$2MFY19Fiscal year ending Dec 2020: revenue —, net income $-59M—FY20Fiscal year ending Dec 2021: revenue $2M, net income $-61M$2MFY21Fiscal year ending Dec 2022: revenue $1M, net income $-66M$1MFY22Fiscal year ending Dec 2023: revenue $3M, net income $-61M$3MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-23M$0MFY24Fiscal year ending Dec 2025: revenue —, net income $-1M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-4M$-1M—
Dec 2024$0M-99.7%$-41M$-23M-233600.0%
Dec 2023$3M+185.6%$-55M$-61M-1818.1%
Dec 2022$1M-32.6%$-67M$-66M-5605.9%
Dec 2021$2M—$-61M$-61M-3460.6%
Dec 2020——$-60M$-59M—
Dec 2019$2M-11.9%$-54M$-51M-2314.0%
Dec 2018$3M—$-51M$-48M-1922.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-4M$0M$-4M$-0.08—
Dec 2024$-32M$0M$-32M$-1.92—
Dec 2023$-52M$0M$-52M$-9.42—
Dec 2022$-57M$1M$-58M$-13.83—
Dec 2021$-52M$1M$-53M$-1.09—
Dec 2020$-40M$0M$-40M$-1.65—
Dec 2019$-75M$1M$-77M$-1.70—
Dec 2018$-42M$6M$-48M$-2.03—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-1M—Dec ’24Three months to Mar 2025: revenue —, net income $0M—Mar ’25Three months to Jun 2025: revenue —, net income $-1M—Jun ’25Three months to Sep 2025: revenue —, net income $-2M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $2M—Dec ’25Three months to Mar 2026: revenue —, net income $1M—Mar ’26Three months to Jun 2026: revenue —, net income $-1M—Jun ’26Three months to Sep 2026: revenue —, net income $-4M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Synlogic, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-4 M
Net income
$-1 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$15 M
Total liabilities
$4 M
Total equity
$12 M

As of December-2025

Top 1 institutional investors in Synlogic, Inc.#

As of Sep 30, 2026
1 institutions held 23,763 shares (about 0.2% of the shares outstanding) on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 13, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 1 largest institutional investors in Synlogic, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1DRW Securities, LLC23,7630 (0.00%)0.19%$0 MNov 13, 2026

Mutual funds holding Synlogic, Inc.#

3 funds hold shares worth $10 M (about 0.0% of the company). Since their previous reports 2 added shares and 0 sold, buying $10 M net.
Mutual funds holding Synlogic, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC1.70 M$6 M—0.19%newJul 31, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC1.20 M$4 M—0.19%newJul 31, 2026
🇺🇸 Large-Cap Growth PortfolioPacific Life Fund Advisors LLC5,323$0 M0.04%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Synlogic, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
31
since
-$3 K$0Apr 2024: bought $0 (0 trades), sold $969 (2 trades)Apr 24Oct 2024: bought $0 (0 trades), sold $111 (1 trades)OctFeb 2025: bought $0 (0 trades), sold $3 K (1 trades)FebApr 2025: bought $0 (0 trades), sold $173 (1 trades)AprOct 2025: bought $0 (0 trades), sold $284 (1 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Synlogic, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Mary Beth DooleySee Remarks belowSell-157$1.810$28412,744Form 4
filed Richard P. SheaDirectorGrant or award+15,000——15,506Form 4
filed James P. FlynnDirectorGrant or award+15,000——15,000Form 4
filed Mary Beth DooleySee Remarks belowSell-144$1.200$17312,901Form 4
filed Mary Beth DooleySee Remarks belowSell-2,107$1.330$3 K13,045Form 4
filed Mary Beth DooleyHead of FinanceSell-79$1.400$11115,152Form 4
filed Antoine AwadChief Operating OfficerSell-372$1.730$64433,859Form 4
filed Mary Beth DooleyHead of FinanceSell-188$1.730$32515,231Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Synlogic, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2,854
0.0% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-7.14 reverse split ; 1-for-14.99 reverse split

Fails to deliver

  • : 500 shares at $1.18
  • : 50 shares at $0.67
  • : 30,555 shares at $0.57
  • : 114,279 shares at $0.56
  • : 1,109 shares at $1.78

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Synlogic, Inc. scorecard#

Passes 3 of the 8 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.08 vs -1.92Diluted EPS -0.08 in fiscal 2025 against -1.92 the year before (report's currency).
    • ✓Net income higher than five years earlier-$1 M-$1 M in fiscal 2025 against -$59 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$1 MNet income -$1 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-8.1%-8.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities4.3×Current ratio 4.30 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.9%Diluted shares up 0.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Synlogic, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Synlogic, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue00.03.41.21.80.52.22.52.40.4
Research and development0.09.24452474742383015r
General and administrative3.56.6151715141516136.4r
Operating expenses4.0415969636157544321r
Operating income−4.0−41−55−67−61−60−54−51−41−21
Interest and finance income—————————0.4
Interest expense and finance costs—00.00.00.00.00.00.00.10.0
Other non-operating income (expense)3.018−6.1r1.30.21.33.02.80.40.0
Income before tax−1.0−23−61r−66——————
Income tax00.00.000000—0
Net income including minority interests−1.0−23−61r−66−61−59−51−48−40—
Net income attributable to shareholders−1.0−23−61r−66−61−59−51−48−40−21r
Earnings per share, basic-0.08-1.92-9.42r-13.83r-1.09-1.65-1.70-2.03-6.00-1.26
Earnings per share, diluted-0.08-1.92-9.42r-13.83r-1.09-1.65-1.70-2.03-6.00-1.26
Shares, weighted average (basic)12126.54.8r55—————
Shares, weighted average (diluted)12126.54.8r553630246.721
Balance sheet
Cash and cash equivalents15192416163326115815r
Short-term investments—02462112689311129—
Other current assets0.00.10.10.2r0.3r0.2r0.6r0.4r0.3r0.0r
Current assets152050801331071331248916r
Property, plant and equipment—05.67.39.11113159.83.5r
Right-of-use (leased) assets—01214141617———
Total assets15207611117514418914010020r
Accounts payable0.10.21.51.81.92.02.22.4r2.71.0r
Current liabilities3.67.130r12108.38.98.39.04.2r
Lease liabilities (non-current)—01216172023———
Non-current liabilities—012161720237.95.62.4
Total liabilities—————————3.8
Retained earnings−443−442−418r−357−291−230−171−120−72−31r
Shareholders' equity121333r83147115157124858.5r
Total liabilities and equity15207611117514418914010020r
Shares outstanding12129.24.4r7038322516—
Cash-flow statement
Depreciation and amortization—————————0.2
Share-based compensation0.13.22.83.63.43.94.14.32.70.4r
Cash from operating activities−4.4−32−52−57−52−40−75−42−31−20r
Capital expenditure0−0.0−0.2−0.7−0.7−0.4−1.3−5.7−2.6−1.8r
Cash from investing activities0.2253958−533211−879.3−1.8r
Shares issued———081—5783—0
Cash from financing activities00.221−2.0891380826731r
Change in cash−4.2−6.18.1−0.6−166.315−4745—
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Synlogic, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2024
$1.3 M
Other top executives, average
$486 K
the CEO earned 2.6× this
$100 invested is now
$4
Synlogic, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2024Chief executive$1.3 M$1.1 M$486 K$4
2023Dr. Aoife Brennan$1.2 M$809 K$667 K$11
2022Dr. Aoife Brennan$1.7 M$659 K$877 K$31

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2024

Events at Synlogic, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Restructuring 1 · Change in control 1 · Directors and officers 10 · Material agreement 2 · Shareholder rights changed 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 6

Synlogic, Inc.: events reported to the SEC
FiledWhat happenedFiling
Change in controlMaterial agreementShareholder rights changed8-K
Delisting notice8-K/A
Delisting notice8-K
Directors and officersShareholder vote8-K
Delisting notice8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Material agreementShareholder rights changedBylaws or fiscal year changed8-K
RestructuringDirectors and officersResults announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jul 29, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Synlogic, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2019$80 MPrivate placement after listing$50 to $250 million1equity, optionsSEC
Mar 2015$42 MNo. 3$10 to $50 million24equitySEC
Oct 2012$17 MNo. 2$10 to $50 million17equitySEC
Aug 2011$2 MNo. 1Under $2 million9equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Synlogic, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2022–2024
Latest
—
2024-02-12
Synlogic, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
2023············—
2022············—
Synlogic, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
90% of workforceRestructuring planSEC 8-K“On February 8, 2024, the Company announced that it is implementing a reduction in workforce by approximately 90%.”Filing
21% of workforceRestructuring planSEC 8-K“The realignment is estimated to reduce the Company’s workforce by approximately 21%.”Filing
25% of workforceRestructuring planSEC 8-K“The realignment is estimated to reduce the Company’s workforce by approximately 25%.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Synlogic, Inc. compares in Biotechnology

  • Revenue growth-99.7% · higher than 0% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Synlogic, Inc.🇺🇸$44 M——-99.7%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Synlogic, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Synlogic, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Synlogic, Inc.? Suggest a correction